For research use only. Not for therapeutic Use.
SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1].
SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM[1].
SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1].
SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1].
| Catalog Number | I042743 |
| CAS Number | 522650-91-5 |
| Synonyms | 2-[(5-propyl-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide |
| Molecular Formula | C21H22N6OS2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H22N6OS2/c1-2-11-27-15-9-5-3-7-13(15)18-19(27)24-21(26-25-18)29-12-17(28)23-20-22-14-8-4-6-10-16(14)30-20/h3,5,7,9H,2,4,6,8,10-12H2,1H3,(H,22,23,28) |
| InChIKey | CTCRADJXWVDTGQ-UHFFFAOYSA-N |
| SMILES | CCCN1C2=CC=CC=C2C3=C1N=C(N=N3)SCC(=O)NC4=NC5=C(S4)CCCC5 |
| Reference | [1]. Yang SY, Li LL. The purposes of 5H- [1,2,4] triazine [5,6-b] indole derivatives of 3 substitutions. CN108309982A. 2017. |
